Literature DB >> 18697883

Neurocognitive correlates of response to treatment in late-life depression.

Tyler J Story1, Guy G Potter, Deborah K Attix, Kathleen A Welsh-Bohmer, David C Steffens.   

Abstract

UNLABELLED: Depression is often associated with neurocognitive deficits in older adults, particularly in the domains of information processing speed, episodic memory, and executive functions. Greater neurocognitive dysfunction while depressed is associated with a less effective treatment response; however, questions remain about the specific variables that characterize patients showing low treatment response and persistent cognitive deficiencies.
OBJECTIVES: The authors examined neurocognitive variables that differentiated patients who showed robust versus weak responses to antidepressant therapy. PARTICIPANTS: The baseline sample included 110 women and 67 men, with a mean age of 69.1 years (SD = 6.9) and mean education of 14 years (SD = 3.3).
DESIGN: Patients enrolled in a treatment study completed both a structured diagnostic assessment for depression and neuropsychological testing at study entry and 1-year follow-up. MEASUREMENTS: Clinicians rated patient depression using the Montgomery-Asberg Depression Rating Scale. Neuropsychological assessments consisted of prose recall and percent retention (Wechsler Memory Scale -III Logical Memory), word-list recall, attention and visuomotor processing speed (Trail Making A, Symbol Digit Modalities Test), and mental flexibility (Trail Making B).
INTERVENTIONS: Patients underwent treatment for depression following the guidelines of the Duke Somatic Treatment Algorithm for Geriatric Depression approach.
RESULTS: Individuals who demonstrated the greatest improvement in mood symptoms at follow-up exhibited better prose recall and faster processing speed at baseline than individuals who demonstrated weaker treatment responses. These differences remained after controlling for depression severity at both time-points.
CONCLUSION: The current results suggest that better pretreatment cognitive function, particularly in verbal memory, is associated with a greater treatment response in late-life depression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18697883      PMCID: PMC2722450          DOI: 10.1097/JGP.0b013e31817e739a

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  46 in total

1.  Changes in cognitive functioning following treatment of late-life depression.

Authors:  M A Butters; J T Becker; R D Nebes; M D Zmuda; B H Mulsant; B G Pollock; C F Reynolds
Journal:  Am J Psychiatry       Date:  2000-12       Impact factor: 18.112

Review 2.  Depression and disability in late life: directions for future research.

Authors:  M L Bruce
Journal:  Am J Geriatr Psychiatry       Date:  2001       Impact factor: 4.105

Review 3.  Frontostriatal and limbic dysfunction in late-life depression.

Authors:  George S Alexopoulos
Journal:  Am J Geriatr Psychiatry       Date:  2002 Nov-Dec       Impact factor: 4.105

4.  Atrophy and high intensity lesions: complementary neurobiological mechanisms in late-life major depression.

Authors:  A Kumar; W Bilker; Z Jin; J Udupa
Journal:  Neuropsychopharmacology       Date:  2000-03       Impact factor: 7.853

5.  The effects of memory, attention, and executive dysfunction on outcomes of depression in a primary care intervention trial: the PROSPECT study.

Authors:  Hillary R Bogner; Martha L Bruce; Charles F Reynolds; Benoit H Mulsant; Mark S Cary; Knashawn Morales; George S Alexopoulos
Journal:  Int J Geriatr Psychiatry       Date:  2007-09       Impact factor: 3.485

6.  Geriatric depression, antidepressant treatment, and healthcare utilization in a health maintenance organization.

Authors:  Lucy Rose Fischer; Feifei Wei; Sharon J Rolnick; Jody M Jackson; William A Rush; Judith M Garrard; Nicole M Nitz; Lori J Luepke
Journal:  J Am Geriatr Soc       Date:  2002-02       Impact factor: 5.562

7.  Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine.

Authors:  Robert D Nebes; Bruce G Pollock; Patricia R Houck; Meryl A Butters; Benoit H Mulsant; Michelle D Zmuda; Charles F Reynolds
Journal:  J Psychiatr Res       Date:  2003 Mar-Apr       Impact factor: 4.791

8.  Course of illness, hippocampal function, and hippocampal volume in major depression.

Authors:  Glenda M MacQueen; Stephanie Campbell; Bruce S McEwen; Kathryn Macdonald; Shigeko Amano; Russell T Joffe; Claude Nahmias; L Trevor Young
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-24       Impact factor: 11.205

9.  The Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED) approach.

Authors:  David C Steffens; Douglas R McQuoid; K Ranga Rama Krishnan
Journal:  Psychopharmacol Bull       Date:  2002

10.  Untreated depression and hippocampal volume loss.

Authors:  Yvette I Sheline; Mokhtar H Gado; Helena C Kraemer
Journal:  Am J Psychiatry       Date:  2003-08       Impact factor: 18.112

View more
  42 in total

1.  The prognostic significance of subsyndromal symptoms emerging after remission of late-life depression.

Authors:  D N Kiosses; G S Alexopoulos
Journal:  Psychol Med       Date:  2012-05-21       Impact factor: 7.723

Review 2.  A Meta-Analysis of Executive Dysfunction and Antidepressant Treatment Response in Late-Life Depression.

Authors:  Monique A Pimontel; David Rindskopf; Bret R Rutherford; Patrick J Brown; Steven P Roose; Joel R Sneed
Journal:  Am J Geriatr Psychiatry       Date:  2015-05-21       Impact factor: 4.105

3.  Physical frailty in late-life depression is associated with deficits in speed-dependent executive functions.

Authors:  Guy G Potter; Douglas R McQuoid; Heather E Whitson; David C Steffens
Journal:  Int J Geriatr Psychiatry       Date:  2015-08-27       Impact factor: 3.485

4.  Depression Remission Rates Among Older Black and White Adults: Analyses From the IRL-GREY Trial.

Authors:  Charles A Hall; Kevin M Simon; Eric J Lenze; Mary Amanda Dew; Amy Begley; Meryl A Butters; Daniel M Blumberger; Jacqueline A Stack; Benoit Mulsant; Charles F Reynolds
Journal:  Psychiatr Serv       Date:  2015-08-17       Impact factor: 3.084

5.  Executive functioning complaints and escitalopram treatment response in late-life depression.

Authors:  Kevin J Manning; George S Alexopoulos; Samprit Banerjee; Sarah Shizuko Morimoto; Joanna K Seirup; Sibel A Klimstra; Genevieve Yuen; Theodora Kanellopoulos; Faith Gunning-Dixon
Journal:  Am J Geriatr Psychiatry       Date:  2013-11-27       Impact factor: 4.105

Review 6.  Brain stimulation in the treatment of late-life severe mental illness other than unipolar nonpsychotic depression.

Authors:  Angela Y Liu; Tarek K Rajji; Daniel M Blumberger; Zafiris J Daskalakis; Benoit H Mulsant
Journal:  Am J Geriatr Psychiatry       Date:  2013-07-23       Impact factor: 4.105

7.  Longitudinal Cognitive Outcomes of Clinical Phenotypes of Late-Life Depression.

Authors:  Meghan Riddle; Guy G Potter; Douglas R McQuoid; David C Steffens; John L Beyer; Warren D Taylor
Journal:  Am J Geriatr Psychiatry       Date:  2017-03-28       Impact factor: 4.105

Review 8.  The vascular depression hypothesis: mechanisms linking vascular disease with depression.

Authors:  W D Taylor; H J Aizenstein; G S Alexopoulos
Journal:  Mol Psychiatry       Date:  2013-02-26       Impact factor: 15.992

9.  Resilience predicts remission in antidepressant treatment of geriatric depression.

Authors:  Kelsey T Laird; Helen Lavretsky; Natalie St Cyr; Prabha Siddarth
Journal:  Int J Geriatr Psychiatry       Date:  2018-07-23       Impact factor: 3.485

10.  FMRI activation during executive function predicts response to cognitive behavioral therapy in older, depressed adults.

Authors:  Dolores Gallagher Thompson; Shelli R Kesler; Keith Sudheimer; Kala Mehendra Mehta; Larry W Thompson; Renee M Marquett; Jason M Holland; Robert Reiser; Natalie Rasgon; Alan Schatzberg; Ruth M O'Hara
Journal:  Am J Geriatr Psychiatry       Date:  2014-02-18       Impact factor: 4.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.